Summit Leadership Spotlights
Comfort in Discomfort: Leadership & Innovation Lessons from an Uncommon Alliance
Can an organization be transformed by the alliance it helps create?
Head, Quality Innovation and Engagement
When the Break Dengue alliance was founded in 2012, its partners didn't expect 250,000 followers in a year, multiple global Awards, and a leading share of voice on dengue. An uncommon alliance in healthcare, Break Dengue has opened new avenues to address critical social issues through public-private-people partnerships.
For Sanofi Pasteur, a founding partner of Break Dengue, it has also posed a serious challenge to its own assumptions and operating modes. Celine Schillinger, now Head of Quality Innovation and Engagement at Sanofi Pasteur, will share the mindset and leadership shift this alliance has triggered at the vaccine manufacturer–the starting point for a remarkable corporate culture transformation. Join Celine to learn how Sanofi Pasteur has focused on creating or accelerating their "Alliance Mindset" and the cultural changes required to do so.
Portrayed in Forbes as "driving some of the most award-winning and buzz-worthy employee initiatives at Sanofi Pasteur", Celine directs Innovation and Engagement for Global Quality at Sanofi's vaccine division. A leader in collaborative projects for business and organizational transformation, Celine has been recognized multiple times for her innovative engagement initiatives in the pharma world. Her career spans communications, business operations, HR, marketing, and social engagement across Asia, Europe and now the United States. A TEDx speaker, Celine is passionate about people-centric innovation to modernize the business environment and increase performance. Celine is a Charter Member of the Change Agents Worldwide think tank.
Accelerating Innovation: Partnering Early and Often in the New Era of Cooperation
Chris Haskell, PhD
Head, U.S. Science Hub
Traditionally, startup companies have built their organizations towards IPO as their main exit strategy, partnering only when necessary. A new era brings a greater focus on 'de-risking before big funding," bringing together startup companies, venture capitalists and academia to engage with Big Pharma much earlier in their path towards developing new therapies for patients. Entrepreneurs and companies are defining new collaboration models through creative partnering pathways, while considering the challenges of addressing the ever-changing industry environment. Join this session and learn how Bayer manages this complex ecosystem, while they create value through innovation.
Dr. Christopher Haskell leads Bayer's U.S. Science Hub, based in the company's U.S. Innovation Center located at Mission Bay, San Francisco. Haskell and his group support Bayer's Drug Discovery through developing and managing partnerships with U.S. academic research institutions and emerging life science firms, including the master agreement signed with UCSF in 2011. Haskell is also responsible for the development of the CoLaborator, a biotech incubator space adjacent to the company's U.S. Innovation Center that opened in 2012 in San Francisco. The CoLaborator houses a number of startup life science firms, and has been developed as a vehicle to foster collaboration between Bayer and these emerging innovators.
Haskell is chair of the California Life Sciences Institute, the San Francisco bay area industry trade organization dedicated to fostering entrepreneurship, science education and workforce development. He is also a board member of the California Life Sciences Association.
After his graduate work at the University of California, Davis and a postdoctoral fellowship at The Gladstone Institute in San Francisco, Haskell joined the Immunology group at Berlex Biosciences. Since joining Bayer in 2007, Haskell has served in various scientific leadership roles, including the Acting Head of Applied Research, the unit responsible for hemostasis research and drug development. In late 2009, Haskell was named head of Bayer's newly formed Science Hub.